Publication date: Dec 25, 2024
LYB001 is a recombinant protein COVID-19 vaccine displaying a receptor-binding domain (RBD) in a highly immunogenic array on virus-like particles (VLPs). This study assessed the immunogenicity and safety of LYB001 as a booster. In this randomized, active-controlled, double-blinded, phase 3 trial, participants aged ≥18 years received a booster with LYB001 or ZF2001 (Recombinant COVID-19 Vaccine). The primary endpoint was to compare the geometric mean titer (GMT) of neutralizing antibodies against Omicron BA. 4/5 at 14 days after the booster. Overall, 1,200 participants aged ≥18 years were enrolled, 599 received LYB001, and 601 received ZF2001. Based on similar baseline level, the 14-day GMT ratio (LYB001/ZF2001) against Omicron BA. 4/5 was 1. 39 (95% CI: 1. 25, 1. 56), demonstrating superiority (95% CI lower limit > 1) of LYB001. The spike protein-binding IgG concentrations induced by LYB001 were significantly higher than those induced by ZF2001 on day 14 and day 28 after the booster (p-value
Open Access PDF
Concepts | Keywords |
---|---|
18years | CHO cell |
Expert | COVID-19 vaccine |
Inactivated | heterologous booster |
Vaccine | immunogenicity |
safety | |
virus-like particle |
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | protein |
disease | IDO | cell |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Ranitidine |
disease | MESH | Infectious Disease |
pathway | REACTOME | Infectious disease |
disease | MESH | COVID 19 pandemic |
disease | MESH | emergency |
drug | DRUGBANK | Amino acids |
disease | IDO | production |
disease | IDO | history |
disease | MESH | allergy |
disease | MESH | anaphylaxis |
disease | MESH | coronavirus infection |
disease | MESH | psychiatric illness |
drug | DRUGBANK | Etoperidone |
drug | DRUGBANK | Aluminum hydroxide |
disease | IDO | site |
disease | MESH | causality |
disease | IDO | blood |
disease | MESH | Seroconversion |
drug | DRUGBANK | Methionine |